Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUC1-activated T cells in relapsed/refractory MUC1-expressing multiple myeloma
NCT05411497Phase 1Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Jun 2022
- Primary completion
- Aug 2027
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous MUC1-activated T-cells in multiple myeloma (MM), sponsored by Mayo Clinic. Primary endpoint: Incidence of adverse events up to 4 years. Started Jun 2022; status: active, not recruiting.
02
Drugs
autologous MUC1-activated T-cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05411497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411497.